Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
47
FONR Quote, Financials, Valuation and Earnings
Last price:
$14.48
Seasonality move
:
5.89%
Day range:
$14.85 - $15.09
52-week range:
$12.00 - $17.62
Dividend yield:
0%
P/E ratio:
13.13x
P/S ratio:
0.88x
P/B ratio:
0.52x
Volume:
27.6K
Avg. volume:
32K
1-year change:
-1.85%
Market cap:
$91.4M
Revenue:
$104.4M
EPS (TTM):
$1.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$285K | -$0.24 | -80.82% | -75.61% | $7.00 |
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
VCYT
Veracyte, Inc.
|
$124.9M | $0.32 | 11.04% | 511.28% | $47.50 |
|
XGN
Exagen, Inc.
|
$16.9M | -$0.16 | 26.43% | -14.75% | $15.43 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FONR
FONAR Corp.
|
$14.52 | -- | $91.4M | 13.13x | $0.00 | 0% | 0.88x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$5.41 | $7.00 | $155.1M | -- | $0.00 | 0% | 32.92x |
|
PRPH
ProPhase Labs, Inc.
|
$0.69 | $13.80 | $3.2M | -- | $0.00 | 0% | 0.47x |
|
VCYT
Veracyte, Inc.
|
$42.92 | $47.50 | $3.4B | 113.07x | $0.00 | 0% | 6.89x |
|
XGN
Exagen, Inc.
|
$6.32 | $15.43 | $143.2M | -- | $0.00 | 0% | 2.01x |
|
XWEL
XWELL, Inc.
|
$0.62 | -- | $3.6M | -- | $0.00 | 0% | 0.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FONR
FONAR Corp.
|
18.59% | 1.654 | 49.09% | 9.64x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-51.52% | -0.107 | 3.29% | 2.57x |
|
PRPH
ProPhase Labs, Inc.
|
52.83% | -0.268 | 40.4% | 0.07x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.341 | 1.49% | 5.74x |
|
XGN
Exagen, Inc.
|
60.83% | 0.117 | 11.39% | 3.63x |
|
XWEL
XWELL, Inc.
|
278.04% | 1.263 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-$423K | -$7.7M | -1767.73% | -1008.03% | -2950% | -$5.6M |
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XGN
Exagen, Inc.
|
$10.1M | -$3.1M | -49.66% | -140.03% | -17.98% | $2.7M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
FONAR Corp. vs. Competitors
-
Which has Higher Returns FONR or IMDX?
Insight Molecular Diagnostics, Inc. has a net margin of 10.25% compared to FONAR Corp.'s net margin of -4174.62%. FONAR Corp.'s return on equity of 5.84% beat Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03%.
Company Gross Margin Earnings Per Share Invested Capital FONRFONAR Corp.40.11% $0.34 $201.3M IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M -
What do Analysts Say About FONR or IMDX?
FONAR Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Insight Molecular Diagnostics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 29.39%. Given that Insight Molecular Diagnostics, Inc. has higher upside potential than FONAR Corp., analysts believe Insight Molecular Diagnostics, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings FONRFONAR Corp.0 0 0 IMDXInsight Molecular Diagnostics, Inc.1 2 0 -
Is FONR or IMDX More Risky?
FONAR Corp. has a beta of 1.000, which suggesting that the stock is 0.021000000000004% less volatile than S&P 500. In comparison Insight Molecular Diagnostics, Inc. has a beta of 1.183, suggesting its more volatile than the S&P 500 by 18.332%.
-
Which is a Better Dividend Stock FONR or IMDX?
FONAR Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FONAR Corp. pays -- of its earnings as a dividend. Insight Molecular Diagnostics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FONR or IMDX?
FONAR Corp. quarterly revenues are $26M, which are larger than Insight Molecular Diagnostics, Inc. quarterly revenues of $260K. FONAR Corp.'s net income of $2.7M is higher than Insight Molecular Diagnostics, Inc.'s net income of -$10.9M. Notably, FONAR Corp.'s price-to-earnings ratio is 13.13x while Insight Molecular Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FONAR Corp. is 0.88x versus 32.92x for Insight Molecular Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FONRFONAR Corp.0.88x 13.13x $26M $2.7M IMDXInsight Molecular Diagnostics, Inc.32.92x -- $260K -$10.9M
-
Which has Higher Returns FONR or PRPH?
ProPhase Labs, Inc. has a net margin of 10.25% compared to FONAR Corp.'s net margin of -774.52%. FONAR Corp.'s return on equity of 5.84% beat ProPhase Labs, Inc.'s return on equity of -90.24%.
Company Gross Margin Earnings Per Share Invested Capital FONRFONAR Corp.40.11% $0.34 $201.3M PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M -
What do Analysts Say About FONR or PRPH?
FONAR Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 19987.34%. Given that ProPhase Labs, Inc. has higher upside potential than FONAR Corp., analysts believe ProPhase Labs, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings FONRFONAR Corp.0 0 0 PRPHProPhase Labs, Inc.0 0 0 -
Is FONR or PRPH More Risky?
FONAR Corp. has a beta of 1.000, which suggesting that the stock is 0.021000000000004% less volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.657, suggesting its less volatile than the S&P 500 by 165.684%.
-
Which is a Better Dividend Stock FONR or PRPH?
FONAR Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FONAR Corp. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FONR or PRPH?
FONAR Corp. quarterly revenues are $26M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. FONAR Corp.'s net income of $2.7M is higher than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, FONAR Corp.'s price-to-earnings ratio is 13.13x while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FONAR Corp. is 0.88x versus 0.47x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FONRFONAR Corp.0.88x 13.13x $26M $2.7M PRPHProPhase Labs, Inc.0.47x -- $883K -$6.8M
-
Which has Higher Returns FONR or VCYT?
Veracyte, Inc. has a net margin of 10.25% compared to FONAR Corp.'s net margin of 14.51%. FONAR Corp.'s return on equity of 5.84% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital FONRFONAR Corp.40.11% $0.34 $201.3M VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About FONR or VCYT?
FONAR Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Veracyte, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 10.67%. Given that Veracyte, Inc. has higher upside potential than FONAR Corp., analysts believe Veracyte, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings FONRFONAR Corp.0 0 0 VCYTVeracyte, Inc.8 2 1 -
Is FONR or VCYT More Risky?
FONAR Corp. has a beta of 1.000, which suggesting that the stock is 0.021000000000004% less volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.829, suggesting its more volatile than the S&P 500 by 82.869%.
-
Which is a Better Dividend Stock FONR or VCYT?
FONAR Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FONAR Corp. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FONR or VCYT?
FONAR Corp. quarterly revenues are $26M, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. FONAR Corp.'s net income of $2.7M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, FONAR Corp.'s price-to-earnings ratio is 13.13x while Veracyte, Inc.'s PE ratio is 113.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FONAR Corp. is 0.88x versus 6.89x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FONRFONAR Corp.0.88x 13.13x $26M $2.7M VCYTVeracyte, Inc.6.89x 113.07x $131.9M $19.1M
-
Which has Higher Returns FONR or XGN?
Exagen, Inc. has a net margin of 10.25% compared to FONAR Corp.'s net margin of -41.1%. FONAR Corp.'s return on equity of 5.84% beat Exagen, Inc.'s return on equity of -140.03%.
Company Gross Margin Earnings Per Share Invested Capital FONRFONAR Corp.40.11% $0.34 $201.3M XGNExagen, Inc.58.43% -$0.31 $46.3M -
What do Analysts Say About FONR or XGN?
FONAR Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Exagen, Inc. has an analysts' consensus of $15.43 which suggests that it could grow by 144.12%. Given that Exagen, Inc. has higher upside potential than FONAR Corp., analysts believe Exagen, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings FONRFONAR Corp.0 0 0 XGNExagen, Inc.8 0 0 -
Is FONR or XGN More Risky?
FONAR Corp. has a beta of 1.000, which suggesting that the stock is 0.021000000000004% less volatile than S&P 500. In comparison Exagen, Inc. has a beta of 1.801, suggesting its more volatile than the S&P 500 by 80.089%.
-
Which is a Better Dividend Stock FONR or XGN?
FONAR Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exagen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FONAR Corp. pays -- of its earnings as a dividend. Exagen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FONR or XGN?
FONAR Corp. quarterly revenues are $26M, which are larger than Exagen, Inc. quarterly revenues of $17.2M. FONAR Corp.'s net income of $2.7M is higher than Exagen, Inc.'s net income of -$7.1M. Notably, FONAR Corp.'s price-to-earnings ratio is 13.13x while Exagen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FONAR Corp. is 0.88x versus 2.01x for Exagen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FONRFONAR Corp.0.88x 13.13x $26M $2.7M XGNExagen, Inc.2.01x -- $17.2M -$7.1M
-
Which has Higher Returns FONR or XWEL?
XWELL, Inc. has a net margin of 10.25% compared to FONAR Corp.'s net margin of -2.87%. FONAR Corp.'s return on equity of 5.84% beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital FONRFONAR Corp.40.11% $0.34 $201.3M XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About FONR or XWEL?
FONAR Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1025.04%. Given that XWELL, Inc. has higher upside potential than FONAR Corp., analysts believe XWELL, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings FONRFONAR Corp.0 0 0 XWELXWELL, Inc.0 0 0 -
Is FONR or XWEL More Risky?
FONAR Corp. has a beta of 1.000, which suggesting that the stock is 0.021000000000004% less volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.697%.
-
Which is a Better Dividend Stock FONR or XWEL?
FONAR Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FONAR Corp. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FONR or XWEL?
FONAR Corp. quarterly revenues are $26M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. FONAR Corp.'s net income of $2.7M is higher than XWELL, Inc.'s net income of -$211K. Notably, FONAR Corp.'s price-to-earnings ratio is 13.13x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FONAR Corp. is 0.88x versus 0.11x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FONRFONAR Corp.0.88x 13.13x $26M $2.7M XWELXWELL, Inc.0.11x -- $7.3M -$211K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
